Suppr超能文献

间皮瘤和肺癌中RB相关基因家族及SV40大T抗原的蛋白表达

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

作者信息

Modi S, Kubo A, Oie H, Coxon A B, Rehmatulla A, Kaye F J

机构信息

Medicine Branch, Division of Clinical Sciences, National Cancer Institute and the National Naval Medical Center, Bethesda, Maryland 20889, USA.

出版信息

Oncogene. 2000 Sep 21;19(40):4632-9. doi: 10.1038/sj.onc.1203815.

Abstract

Mutational inactivation of the RB-related gene RBL2/p130 has been reported as a common and important prognostic factor in human lung cancer. To examine the role of the RB-related gene family in lung cancer we analysed the protein expression of the RB gene in cell lines obtained from 83 patients with small cell lung cancer (SCLC) and 114 patients with non-SCLC that included 21 novel lung tumor samples. While we detected five new SCLC with mutant RB expression (RB inactivation in 75/83; 90.4%), we did not detect any RB mutations in the new non-SCLC cell lines (RB inactivation in 13/114 non-SCLC and mesothelioma; 11.4%). In addition, we detected expression of a full-length RBL1/p107 and RBL2/p130 species in every sample tested (RBL1 or RBL2 inactivation in 0/69) and confirmed that both RB-related gene products retain functional binding activity to the E1A viral oncoprotein. Since expression of SV40 Large T antigen (Tag) has been reported in a subset of human lung tumors where it may inactivate RBL1 and RBL2, we also examined mesothelioma and non-mesothelioma lung tumors for Tag expression. Although we detected a faint 85 kDa protein species using specific anti-Tag antibodies, this signal migrated slightly faster than Tag extracted from Cos7 cells and did not exhibit binding activity to the RB or RBL1 proteins. Finally, we subjected 11 lung cancer cell lines to nucleotide sequencing and did not detect mutations within the C-terminal RBL2 exons 19-22 as recently reported. While the RB/p16 tumor suppressor pathway is targeted for mutations in 100% of lung cancers, mutational inactivation of the related RBL1 and RBL2 genes is a rare event.

摘要

据报道,RB相关基因RBL2/p130的突变失活是人类肺癌常见且重要的预后因素。为了研究RB相关基因家族在肺癌中的作用,我们分析了从83例小细胞肺癌(SCLC)患者和114例非小细胞肺癌患者(包括21个新的肺肿瘤样本)获得的细胞系中RB基因的蛋白表达。虽然我们检测到5个新的SCLC具有突变型RB表达(83例中有75例RB失活;90.4%),但在新的非小细胞肺癌细胞系中未检测到任何RB突变(114例非小细胞肺癌和间皮瘤中有13例RB失活;11.4%)。此外,我们在每个测试样本中都检测到了全长RBL1/p107和RBL2/p130蛋白的表达(69例中RBL1或RBL2失活为0例),并证实这两种RB相关基因产物对E1A病毒癌蛋白均保留功能性结合活性。由于在一部分人类肺肿瘤中已报道有SV40大T抗原(Tag)表达,它可能使RBL1和RBL2失活,我们还检测了间皮瘤和非间皮瘤性肺肿瘤中的Tag表达。虽然我们使用特异性抗Tag抗体检测到一种微弱的85 kDa蛋白条带,但该信号迁移速度略快于从Cos7细胞中提取的Tag,且对RB或RBL1蛋白未表现出结合活性。最后,我们对11个肺癌细胞系进行了核苷酸测序,未检测到最近报道的C末端RBL2外显子19 - 22内的突变。虽然RB/p16肿瘤抑制途径在100%的肺癌中都有突变靶点,但相关的RBL1和RBL2基因的突变失活却是罕见事件。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验